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Abstract
Background: Glioblastoma multiforme (GBM) is characterized by extensive local invasion, which is in contrast with
extremely rare systemic metastasis of GBM. Molecular mechanisms inhibiting systemic metastasis of GBM would be
a novel therapeutic candidate for GBM in the brain.
Methods: Patient-derived GBM cells were primarily cultured from surgical samples of GBM patients and were
inoculated into the brains of immune deficient BALB/c-nude or NOD-SCID IL2Rgammanull (NSG) mice. Human NK
cells were isolated from peripheral blood mononucleated cells and expanded in vitro.
Results: Patient-derived GBM cells in the brains of NSG mice unexpectedly induced spontaneous lung metastasis
although no metastasis was detected in BALB/c-nude mice. Based on the difference of the innate immunity
between two mouse strains, NK cell activities of orthotopic GBM xenograft models based on BALB/c-nude mice
were inhibited. NK cell inactivation induced spontaneous lung metastasis of GBM cells, which indicated that NK
cells inhibit the systemic metastasis. In vitro cytotoxic activities of human NK cells against GBM cells indicated that
cytotoxic activity of NK cells against GBM cells prevents systemic metastasis of GBM and that NK cells could
be effective cell therapeutics against GBM. Accordingly, NK cells transplanted into orthotopic GBM xenograft
models intravenously or intratumorally induced apoptosis of GBM cells in the brain and showed significant
therapeutic effects.
Conclusions: Our results suggest that innate NK immunity is responsible for rare systemic metastasis of GBM
and that sufficient supplementation of NK cells could be a promising immunotherapeutic strategy for GBM in
the brain.
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Background
Glioblastoma multiforme (GBM) is the most common
primary malignancy of the central nervous system
(CNS), and 75 % of affected patients die within two years
of their diagnosis [1–3]. GBMs are characterized by their
highly infiltrative nature, which causes difficulties in
curative surgical resection. Moreover, the resistance of
GBM cells to radio- and chemo-therapy provokes a high
rate of tumor recurrence [2, 4, 5]. Therefore, unmet
medical need new therapeutic modalities with novel
treatment mechanisms targeting GBM cells that evade
and/or withstand currently available therapies.
Although GBMs are known as highly invasive tumors
in the brain, extra-cranial metastasis does rarely occur
[6–9]. This clinical characteristic of GBMs could be due
to several reasons; short survival length of GBM patients,
unique structure of micro-vessels in the CNS, lack of
lymphatic systems in the CNS, and immune-privileged
microenvironments [10–12]. The underlying mechanisms
of the limited systemic metastatic potential of GBM cells
are not only interesting from a scientific perspective, but
could also provide clues leading to novel therapeutic mo-
dalities and unique treatment mechanisms.
Recently, orthotopic GBM xenograft animal models
using patient-derived GBM cells have been utilized to
test newly developed therapeutic agents of GBMs [13]. The
animal models maintain the genetic, molecular, and func-
tional features of the parental tumors to provide reliable
preclinical models for GBMs. Since the xenograft models
utilize immune deficient mouse strains to avoid graft rejec-
tion, immunologic microenvironments of transplanted
GBM cells can be specifically modified by choosing a re-
cipient mouse strain with defined immune deficiency sta-
tus. For example, the BALB/c-nude strain has an innate
immune system but no acquired immunity, while both the
innate and acquired immune systems of the NOD-scid
IL2Rgammanull (NSG) mouse are impaired [14–16].
In this study, we elucidated a possible mechanism re-
garding the limited systemic metastatic potential of
GBM cells in the brain using an orthotopic xenograft
animal model in addition to discovering some anti-
cancer activities of systemic NK cells. Since the brain
microenvironments prevent GBM cells from having dir-
ect contact with NK cells, direct or indirect NK cell sup-
plementation to the GBMs demonstrated significant
therapeutic effects, in our preclinical model.
Methods
Cell culture
All Human samples were collected with written informed
consent under a protocol approved by the Institutional Re-
view Board of the Samsung Medical Center (2010–04–004,
Seoul, Korea). Parts of the surgical samples were enzymati-
cally dissociated, and then red blood cells were removed by
percoll gradient centrifugation (Sigma-Aldrich). Dissociated
cells were maintained in the ‘NBE’ conditions consisting of
Neuro-Basal Media, N2 and B27 supplements (×1/2 each),
2 mM L-glutamine, 100U/ml penicillin and streptomycin
(Invitrogen), and human recombinant EGF and bFGF
(50 ng/ml each; R&D Systems). The human GBM cell
line U-87 MG (ATCC) was maintained in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with
10 % fetal bovine serum, 100U/ml penicillin and
streptomycin (Invitrogen).
Patient-derived GBM xenograft model
All animal experiments were approved by the Institu-
tional Review Boards of the Samsung Medical Center
(Seoul, Korea) and conducted in accord with the ‘Health
Guide for the Care and Use of Laboratory Animals’
(NIH publication no. 80–23) and the ARRIVE guidelines
for Reporting Animal Research [17] (Additionanl file 1).
For orthotopic GBM xenograft models, anesthetized 6-
week-old BALB/c-nude or NOD-SCID IL2Rgammanull
(NSG) mice were secured in a rodent stereotactic frame
(mice were obtained from Orient Bio Korea). A hollow
guide screw was implanted into a small drill hole made at
2 mm left and 1 mm anterior to the bregma, and then 2 ×
105 tumor cells in 5 μl HBSS were injected through this
guide screw into the white matter at a depth of
2 mm [anterior/posterior (AP) +0.5 mm, medial/lat-
eral (ML) +1.7 mm, dorsal/ventral (DV) -3.2 mm].
Mice with a total body weight reduction >20 % were
sacrificed, and their brains and lungs were processed
for paraffin sections.
Treatment with anti-asialo GM1 (ASGM1) antibody
Male 6-week-old BALB/c-nude mice were injected intra-
venously with the ASGM1 antibody (Wako Chemicals)
or 1× Phosphate Buffered Saline (PBS, Invitrogen) on
Day -1 (40 μl/ea). On Day 0, patient-derived GBM cells
(2 × 105) were implanted into the brain as described pre-
viously. After the tumor cell inoculation, either ASGM1
antibody or 1× PBS were intravenously injected into the
animals twice a week for 4.5 months. Eighteen weeks
after the tumor cell inoculation, the mice were sacrificed.
Spleens were harvested and measured NK cells activity.
Brains and lungs were paraffin-embedded, and then
sliced into 4 μm sections for histological analysis.
For murine NK cell activity measurement, the spleens
were immersed in Hank's Balanced Salt Solution (HBSS,
Invitrogen), and then single cell suspensions were pre-
pared by forcing the spleens through a 70 μm nylon
mesh. The resulting cell suspension was placed onto a
Ficoll-Paque PLUS (GE Healthcare) and centrifuged for
30 min at 2,000 rpm. Mononuclear cells were isolated,
washed, and stained with a PE-Cy7-conjugated anti-
mouse CD314 (NKG2D) antibody (eBioscience).
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Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized
and rehydrated. Heat-induced epitope retrieval was per-
formed using a target retrieval solution (Dako) for 5 min
in a microwave. Slides were treated with 3 % hydrogen
peroxide for 10 min to inactivate endogenous peroxid-
ase, and then the slides were blocked for 20 min at room
temperature in a blocking solution (5 % normal horse
serum, 1 % normal goat serum, 0.1 % Triton-X 100 in
1× PBS). After blocking, the slides were incubated in pri-
mary antibodies at 4 °C overnight; including mouse
monoclonal antibody against human Ki-67 (BD Phar-
mingen), mouse monoclonal antibody against human
cytoplasm (STEM-121, Stem Cells), mouse monoclonal
antibody against human nestin (Thermo), mouse monoclo-
nal antibody against human SOX2 (Cell Signaling technol-
ogy), mouse monoclonal antibody against human GFAP
(Sigma), mouse monoclonal antibody against NK1.1
(Novus biological), and rabbit monoclonal antibody against
human HLA-A (MHC class I, abcam). Slides were washed
and incubated with secondary antibodies for 1 h at room
temperature [Avidin-Biotin complex kit (Vector lab) or
Alexa Flour 488 or 594 conjugated antibodies (Invi-
trogen)]. Slides were counterstained with hematoxylin
(Sigma-Aldrich) or DAPI (Sigma-Aldrich).
Western blotting and flow cytometry
Cell lysates were prepared using lysis buffer (50 mM
HEPES, pH7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 % Triton
X-100, 10 % glycerol, and protease/phosphatase inhibitors;
Roche). Protein concentrations were determined using a
BCA protein assay kit according to the manufacturer's di-
rections (Thermo). Equivalent amounts of proteins were
separated by 10 % SDS gel electrophoresis, transferred onto
PVDF membranes (Thermo), and immunoblotted with pri-
mary antibodies overnight at 4 °C, including a rabbit
monoclonal antibody against human HLA-A (MHC class I,
abcam) and a rabbit monoclonal antibody against GAPDH
(Cell Signaling technology). Antibodies were visualized
using a horseradish peroxidase-conjugated anti-rabbit IgG
(Thermo) and analyzed using enhanced chemilumines-
cence western blot detection reagent (GE Healthcare).
For flow cytometry, anti-HLA-ABC-PE (G46-2.6),
anti-MIC-A/B-PE (6D4) (BD Biosciences), anti-ULBP-1-
PE (170818), anti-ULBP-2-PE (165903) (R&D systems),
anti-HLA-E-PE (3D12), anti-CD112-PE (TX31), and
anti-CD155-PE (SKII.4) antibody (BioLegend) were uti-
lized. Samples were run on a BD Fortessa (BD Biosci-
ences) and data were analyzed using FlowJo software
(TreeStar Inc., OR).
Human NK cell preparation and in vitro expansion
In vitro expansion of human NK cells was conducted as
previously described [18]. Briefly, peripheral blood
mononucleated cells (PBMCs) were isolated from healthy
donors by leukapheresis and CD3+ T cells were depleted by
VarioMACS (Miltenyi Biotech). T cell-depleted PBMCs
were expanded at a seeding concentration of 2 × 105 cells/
ml in CellGro SCGM serum-free medium (CellGenix) with
1 % autoplasma, 1 × 106 cells/ml irradiated (2,000 rad) au-
tologous PBMCs, 10 ng/ml anti-CD3 monoclonal antibody,
OKT3 (Orthoclon), and 500 IU/ml IL-2 (Proleukin) in an
A-350 N culture bag (NIPRO). On day 5 of culture, NK
cells were fed with fresh medium containing 500 IU/ml IL-
2 and 1 % autoplasma every two days without removal of
preexisting culture medium to maintain a cellular concen-
tration at 1 ~ 2 × 106 cells/ml for 14 days. The viability of
expanded NK cells was determined by propidium iodide
staining.
In vitro expanded NK cells were stained with primary
antibodies and analyzed by a flow cytometry using anti-
CD56-PE-Cy5 (B159), anti-CD16-PE (3G8), anti-CD3-
FITC (UCHT1), anti-NKp30-PE (P30-15), anti-NKp44-PE
(P44-8.1), anti-NKp46-PE (9E2/NKp46), anti-DNAM-1-PE
(DX11), anti-CD14-FITC (M5E2), anti-CD19-PE (HIB19)
(BD Biosciences), anti-NKG2D-PE (149810) (R&D sys-
tems), anti-CD158a-PE (EB6Bf), anti-CD158b-PE (GL183),
and anti-CD158e-PE (Z27.3.7) (Beckman Coulter).
51Cr-release cytotoxicity assay
Target cells were labeled with 100 μCi 51 Cr sodium chro-
mate (BMS), and incubated with NK cells in U-bottom
96-well plates (BD falcon) at three different effector:target
(E:T) ratios. Spontaneous and maximum releases were de-
termined by incubating target cells without effector cells
in the absence or presence of 4 % Triton X-100. Radio-
activity was counted using a gamma counter (PerkinEl-
mer), and the percentage of specific lysis was calculated as
follows: % specific lysis = [(experimental release–spontan-
eous release)/(maximum release-spontaneous release)] ×
100. The assay was performed in triplicate.
In vivo anti-tumor activities of NK cells
Orthotopic GBM xenograft models were established as
described previously, using 2 × 105 U-87 MG cells in
5 μl HBSS were injected in male 6-week-old BALB/c-
nude mice brains. Human NK cells were injected intra-
tumorally (1 × 103, 1 × 104, 1 × 105 in 5 μl HBSS) or
intravenously (1 × 105, 1 × 106, 1 × 107, in 100 μl HBSS)
into animals once a week for 3 weeks or 3 times a week
for 1 week. After 28 days, the animals’ brains were har-
vested and cut into 4–6 mm thick slices.
Brain slices were fixed in 4 % paraformaldehyde, em-
bedded in paraffin, sectioned into 4 μm coronal sections
using a microtome, and stained with hematoxylin and
eosin (Sigma). The tumor volume was calculated by
measuring the section with the largest tumor portion
and applying the formula: (width)2 × length × 0.5. The
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DeadEnd™ Colorimetric TUNEL System (Promega) was
used to assay apoptosis. For human NK cell detection,
immunohistochemistry was performed using a mouse
monoclonal antibody against CD56 (Dako). Numbers of
human NK cells or TUNEL-positive cells were counted
in 5 randomly selected fields for each mouse.
Statistical analysis
Data are presented as mean + standard deviation (SD) or
standard error (SE). Statistical comparisons of groups
were performed using the Student’s t test. Values of
P <0.05 were considered to be statistically significant.
Results
Spontaneous lung metastasis of patient-derived GBM cells
in orthotopic xenograft animal models using NSG mice
One of issues that could increase the translational value
of the orthotopic xenograft model using patient-derived
GBM cells, is an experimental protocol that would im-
prove the in vivo tumor-take rate and shorten the latent
period for the formation of detectable xenograft tumors.
We hypothesized that recipient mouse strains with dif-
ferent levels of immune deficiency could be independent
experimental variables that make a difference in the es-
tablishment of a GBM orthotopic xenograft model.
Based on the hypothesis, we adopted two immune defi-
cient mouse strains, BALB/c-nude and NSG mice, and
then four types of patient-derived GBM cells were
stereotactically injected into the mice’s brains (Table 1).
Compared with the BALB/c-nude strain, NSG mice have
a greater immune deficiency, including an impaired in-
nate immune system [16]. In vivo tumorigenicity was de-
fined as the formation of a tumor within the 6 months
after tumor cell transplantation [13]. Overall in vivo
tumor-take rates were not different between the BALB/
c-nude and NSG groups (Table 1). However, median sur-
vivals of the NSG groups were significantly shorter than
those of the BALB/c-nude groups (P < 0.001 for GBM-1,
GBM-2, and GBM-3, P < 0.01 for GBM-4, Table 1),
which indicates that the level of immune deficiency
could have an effect on the orthotopic in vivo tumor for-
mation of patient-derived GBM cells. Orthotopic xeno-
graft tumor formation was confirmed by the pathology
and immunohistochemistry against the proliferation
marker, Ki-67 (Fig. 1a).
Unexpectedly, we detected abnormal respiratory
movements in the NSG groups. Although extra-cranial
metastasis of GBMs is extremely rare in GBM patients
[7–9] the abnormal behavior observed suggested a spon-
taneous lung metastasis of orthotopically-implanted
patient-derived GBM cells. When the lungs of both the
BALB/c-nude and NSG groups were harvested, multiple
visible lung nodules were observed only in the NSG
groups (Table 1, arrowheads in Fig. 1a). The oncologic
origin of the nodules was confirmed by the pathology
and immunohistochemistry against Ki-67 (Fig. 1a). The
lung nodules in the NSG mice were consistently de-
tected in all four kinds of patient-derived GBM cells
(Fig. 1b). Compared with the BALB/c-nude mouse, the
NSG mouse strain has severe impairments, not only in
adaptive T- and B-cell activities but also in innate im-
munity, involving macrophages and natural killer (NK)
cells. Since metastasizing GBM cells meet circulating
immune cells in the blood stream, we hypothesized that
presence of NK cells in the circulating system might
cause those sharp differences in the extra-cranial meta-
static potential of implanted patient-derived GBM cells.
Spontaneous extra-cranial metastasis of GBM cells pro-
voked by NK cell-inactivation in BALB/c-nude mice
To evaluate our hypothesis, we inactivated NK cells in
BALB/c-nude mice using an activated NK cell-inhibition
ASGM1 antibody [19–21] and then orthotopically trans-
planted patient-derived GBM cells (2 × 105/ea, GBM-3)
(Fig. 2a). ASGM1 treatment (2 times/week) was main-
tained for 4.5 months, the median survival time of
BALB/c-nude orthotopic xenograft animal model using
GBM-3 cells (Table 1). ASGM1-treated mice showed
Table 1 In vivo tumor formation rate and median survival length of orthotopic GBM xenograft animal models
Patient.no. Mouse Mouse number (Tumor formation/Total) Median survival day
Brain Lung
GBM-1 BALB/c-nude 4/5 (80 %) 0/5 (0 %) 206
NSG 4/5 (80 %) 2/5 (40 %) 176***
GBM-2 BALB/c-nude 4/5 (80 %) 0/5 (0 %) 130
NSG 3/5 (60 %) 4/5 (80 %) 91***
GBM-3 BALB/c-nude 3/5 (60 %) 0/5 (0 %) 145
NSG 3/5 (60 %) 2/5 (40 %) 121***
GBM-4 BALB/c-nude 4/5 (80 %) 0/5 (0 %) 140
NSG 4/5 (80 %) 3/5 (60 %) 120**
**p < 0.01, ***p < 0.001
Lee et al. BMC Cancer  (2015) 15:1011 Page 4 of 13
Fig. 1 (See legend on next page.)
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significantly fewer NKG2D-positive NK cells in the
spleen than PBS-treated control mice, indicating the
successful inactivation of systemic NK cells (Fig. 2b).
When the control and NK cell-inactivated mice were
sacrificed simultaneously (Fig. 2a), orthotopic brain
tumor take-rates were not different (Fig. 2c, n = 5 for
each group). In contrast, lung nodules were observed
only in the ASGM1-treated mice (Fig. 2d, 60 % of the
treated mice). The oncologic origin of the nodules was
confirmed by the pathology and immunohistochemistry
against Ki-67 (Fig. 2d). We further performed immuno-
histochemistry against human specific cytoplasmic anti-
gen (STEM-121) and GBM specific markers (GFAP,
Nestin, and SOX2) to confirm that the lung nodules
were composed with human GBM cells. Cells in the lung
nodules expressed all human-specific or GBM-specific
antigens (Fig. 2e), and the antigens were co-localized in
same cells (Fig. 2f ). These results indicate that NK cells
are responsible for the inhibition of extra-cranial metas-
tasis of patient-derived GBM cells in BALB/c-nude mice.
Although it is not included in this study, it need to be
elucidated further whether NSG mice with GBM cells in
their brains have fewer lung metastases when they are
supplemented with NK cells.
NK cell distribution in orthotopic GBM xenografts and MHC
class I molecule expression of patient-derived GBM cells
NK cells affected the extra-cranial metastasis of patient-
derived GBM cells in BALB/c-nude mice but not in ortho-
topic brain tumor formation. NK cells have been suggested
to be involved in xenograft rejections although their mo-
lecular mechanism has yet to be elucidated [14, 22]. Since
the brain is an immunologically privileged organ [23], the
absence of NK cells in the brain could result in the extra-
cranial metastasis-specific effects. When we performed im-
munohistochemistry against NK1.1, a NK cell marker, in
the orthotopic xenograft tumors, NK1.1-positive cells were
hardly observed in the BALB/c-nude mice (Fig. 3a). We
also evaluated MHC class I molecule expression of patient-
derived GBM cells in the orthotopic xenograft animal
model, since MHC class I molecules give inhibitory signals
to NK cells [1, 24, 25]. Although patient-derived GBM cells
expressed MHC class I molecules, the expression was
very heterogeneous; as some cells did not show im-
munoreactivity to the antibody against MHC class I
molecules (Fig. 3b, c).
The absence of NK cells in brain tumor and heteroge-
neous MHC class I molecule expression of GBM cells
suggest followings. First, engraftment of patient-derived
GBM cells could be more successful in the brain than
other organs that have reactive NK cells. Second, circu-
lating NK cells could target metastasizing GBM cells in
extra-cranial sites. Previously, invasive GBM cells were
observed to lose expression of MHC class I molecules
[26], which would increase the possibility that NK cells
might recognize invasive and/or migrating GBM cells.
Applicability of NK cell therapy to GBM
The absence of NK cells in brain tumors and the anti-
cancer effects of NK cells inversely indicate that supple-
mentation of reactive NK cells to GBMs could have
therapeutic effects. To evaluate the possibility, we trans-
ferred NK cells to an orthotopic xenograft GBM animal
model and its examined therapeutic effects. In the clinic,
mouse NK cells could not be hired to treat human
GBMs. To address this issue, human NK cells were uti-
lized for the experiments.
Large-scale expansion of human NK cells
Human peripheral blood mononuclear cells (PBMCs)
were isolated from healthy volunteers, and then CD3
positive T cells were depleted by MACS using an anti-
CD3 antibody. The resulting T cell-depleted PBMCs were
co-cultured with irradiated autologous PBMCs in the
presence of IL-2 and OKT-3 for 14 days. The expanded
cells were composed of highly enriched CD3-CD56+
(95.74 ± 3.48 %) or CD56+CD16+ (84.05 ± 11.61 %) NK
cells with minimal contamination by CD3+ T cells (0.59 ±
0.72 %), CD14+ monocytes (0.36 ± 0.51 %), and CD19+ B
cells (0.12 ± 0.13 %) (Fig. 4a). During the culture, NK cells
substantially expanded 319.40 ± 210.4-fold (Fig. 4b) with
had a viability of 90.91 ± 6.68 % (Fig. 4c). Expanded NK
cells showed high-level expression of activating receptors
such as NKG2D, NKp30, NKp44, NKp46, and DNAM-1,
suggesting their potent effector functions (Fig. 4d). Fur-
thermore, expression of inhibitory KIR receptors
(CD158a, CD158b, and CD158e) indicated that the ex-
panded NK cells were sufficiently matured (Fig. 4e).
In vitro GBM cell lysis effects of expanded NK cells
Cytotoxic activity of expanded NK cells against human
GBM U-87 MG and human immortalized myelogenous
leukemia K562 (positive control) cells was evaluated in
vitro. Compared with K562 cells, U-87 MG cells
expressed MHC class I (HLA-ABC) molecules highly
(Fig. 5a). However, U-87 MG cells also have high levels
(See figure on previous page.)
Fig. 1 Brain and metastatic lung tumor formation in an orthotopic xenograft animal model using patient-derived GBM cells. a Pathologic validation of
brain and metastatic lung tumors in various orthotopic xenograft animal models (n = 5 for each group). Tumor cells were transplanted into the mouse
brain parenchyma. Immunohistochemistry against a cell proliferation marker (Ki-67) was performed. b Metastatic lung tumor formation rate was
compared between BALB/c-nude and NSG recipient mouse strains
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of NK cell-activating ligands such as CD112 and CD155
(DNAM-1 ligands) (Fig. 5a). When U-87 MG or K562 cells
were co-cultured with expanded human NK cells (NK
cell:tumor cells = 3:1, 1:1, or 0.3:1), NK cells lysed cancer
cells in a dose-dependent manner (Fig. 5b). Since U-87
MG GBM cells express NK cell-inhibiting MHC class I
molecules and have less NK cell-activating ligands (Fig. 5a),
the cytotoxicity of NK cells was more prominent in K562
cells (Fig. 5b). These results suggest that GBM cells have a
susceptibility to NK cells and that the balance between the
inhibitory and activating signals for NK cell could be an
important determinant of NK cell effects on target cells.
In vivo therapeutic effects of NK cells against orthotopic
GBM xenograft tumors
Next, the in vivo therapeutic efficacy of NK cells against
GBM was examined. NK cells were injected intratumorally
(1 × 103, 1 × 104, or 1 × 105 in 5 μl HBSS) or intravenously
(1 × 105, 1 × 106, or 1 × 107 in 100 μl HBSS) into BALB/c-
nude mice bearing U-87 MG tumors in their brains once a
week for three weeks (control = intravenous HBSS only,
each group n = 7; Fig. 6a). When tumor volumes were
measured one week after the last NK cell injection, the
intratumoral NK cell injection groups showed significantly
smaller tumors in a dose-dependent manner. Compared
with the control group, the 1 × 103, 1 × 104, and 1x105
intratumoral injection groups showed 36, 57, and 56 %
tumor volume reduction, respectively (Fig. 6b). When NK
cells were injected intravenously, the 1 × 107 intravenous
injection group showed a 60 % reduction in tumor volume
(P < 0.001 vs. control), while the other intravenous injec-
tion groups had no statistically significant treatment effects
(Fig. 6b). Significant increase in the numbers of TUNEL-
positive apoptotic cells (Fig. 6c) were confirmed by
(See figure on previous page.)
Fig. 2 NK cell inactivation provokes spontaneous lung metastasis of GBM cells in the brains of BALB/c-nude mice. a Experimental schedule illustrated.
b Murine splenic NK cells were analyzed by flow cytometry. NKG2D-posive cell ratio was analyzed and compared. c, d Pathologic validation of brain
(c) and metastatic lung tumors (d) in various orthotopic xenograft animal models. Immunohistochemistry against a cell proliferation marker (Ki-67) was
performed. e Immunohistochemistry against human specific cytoplasmic antigen (STEM-121) and GBM specific markers (GFAP, Nestin and SOX2) in
metastatic lung tumors. f Human-specific cytoplasmic antigen (STEM-121) was co-localized with GBM specific markers (GFAP or Nestin)
Fig. 3 Expression of NK1.1 and MHC class I molecules in orthotopic GBM xenograft tumors. a NK cells were immunostained with a specific antibody
against NK1.1 in the orthotopic GBM xenograft tumors. b, c MHC class I molecule expression of patient-derived GBM cells were analyzed by western
blotting (b) and immunohistochemistry in the orthotopic GBM xenograft tumors (c). GAPDH= loading control
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immunohistochemistry in the 1 × 104 intratumoral and
1 × 107 intravenous injection groups. These results sug-
gested that in vivo treatment of supplementation of NK
cells has positive effects against orthotopic GBM xenograft
tumors. Although fewer number (1 × 104) of NK cells were
intratumorally injected compared with the intravenous
transplantation group (1 × 107), similar numbers of NK
cells were observed in the orthotopic GBM xenograft tu-
mors (Fig. 6d) 24 h after the transplantation of NK cells
(Fig. 6a). Since the two groups had similar treatment re-
sults (Fig. 6b), these results indicated that direct cell-to-
cell interaction induced by infiltration of NK cells into the
tumors in the brain parenchyma is required for the cyto-
toxic effects of NK cells.
Implications of treatment schedule in the NK cell therapy
against GBM
Although the intratumoral injection of NK cells needed
fewer cell numbers for in vivo treatment results, intra-
venous injection is more clinically applicable. To in-
crease the NK cell-cancer cell interaction of intravenous
treatment, we modified the treatment schedule from 1 ×
107 NK cells once a week for 3 weeks to 1 × 107 NK cells
three times a week for a week (Fig. 7a). The concen-
trated treatment would increase NK cell/tumor cell ratio
in the brain tumor. Compared with once a week sched-
ule (60 % tumor volume reduction compared with the
HBSS intravenous injected control group), the three
times a week treated group showed better treatment
Fig. 4 Large-scale in vitro expansion human NK cells and their phenotypic characteristics. a The expanded human NK cells were analyzed for various
immune cell markers (n = 22). b The fold expansion of NK cells was determined by comparing the numbers of NK cells in the culture before (D0) and
after (D14) the expansion (n = 20). c The viability of expanded NK cells was measured through propidium iodide staining (n = 20). Surface expression of
activating (d) and inhibitory (e) receptors on expanded NK cells was analyzed by flow cytometry (n = 13). Data =mean + SD for (d) and (e)
Fig. 5 GBM cell lysis effects of expanded human NK cells. a Surface expression of HLA-ABC, HLA-E, NKG2D ligands (MIC-A/B, ULBP-1, and ULBP-2),
and DNAM-1 ligands (CD112, CD155) on tumor cells was analyzed by flow cytometry. b In vitro cytotoxicity of expanded NK cells against K562
and U-87 MG cells was determined by 51Cr-release assay. Data =mean ± SD
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results (86 % tumor volume reduction) (Fig. 7b, n = 7 for
each group). Therefore, optimized treatment schedules
would potentiate the therapeutic effect of intravenous
NK cell supplementation treatment against GBM.
Discussion
In this study, we observed the spontaneous systemic me-
tastasis of patient-derived GBM cells that were
inoculated into the brains of NSG mice. Since the sys-
temic metastasis was not induced in the BALB/c-nude
mice, we hypothesized that the difference originates
from the innate immune system such as NK cells, mac-
rophages, and the complement system [14, 16, 22].
When we administrated murine NK cell inhibition anti-
body to BALB/c-nude orthotopic GBM animal models,
extra-cranial metastases were induced. These results
Fig. 6 In vivo therapeutic effects of human NK cells against orthotopic GBM xenograft tumors. a Experimental schedule illustrated. b Tumor volumes were
determined and compared one week after the last NK cell injection (n= 7 for each group). I.T. = intratumoral transplantation, I.V. = intravenous injection.
Data =mean + SE. *p < 0.05, ***p < 0.001, vs. control. c Apoptotic tumor cells in the xenograft tumors were analyzed by the TUNEL assay. TUNEL-positive
cells were calculated and compared with the control group. Arrow= TUNEL positive cell, Data =mean + SE. ***p < 0.001, vs. control. d Human NK cells were
traced by immunohistochemistry using a CD56-specific antibody (n= 3 for each group). Number of NK cells were calculated and compared with the
control group. Arrow= CD56 positive cell, Data =mean + SE. ***p < 0.001, vs. control
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suggest that NK cells play an important inhibitory role
in the systemic metastasis of GBMs and that GBM cells
are sensitive to the cytotoxic activities of NK cells.
Traditionally, the brain has been regarded as an im-
munologically privileged site [2, 4, 5, 27, 28]. In orthoto-
pic GBM xenograft tumors, NK cells were not observed
by immunohistochemistry in this study. NK cells identify
and eliminate cells lacking MHC class I molecules,
which are dependent on the activation status of NK cell-
activating and inhibitory receptors [29–33]. We ob-
served that the expression of MHC class I molecules in
patient-derived GBM cells is heterogeneous. However,
ly49 receptors of mouse NK cells could not recognize
human MHC class I molecules [34–37]. Therefore, NK
cells of BALB/c-nude mice would target human patient-
derived GBM cells, while human patient-derived GBM
cells in the brain parenchyma could not have direct con-
tacts with NK cells.
In vitro expanded human NK cells showed cytotoxic
effects against human U-87 MG GBM cells in vitro and
in vivo, although U-87 MG cells expressed NK cell-
inhibiting MHC class I molecules (HLA-ABC). These
unexpected results might originate from the expression
of NK cell-activating ligands of U-87 MG cells such as
ULBP-2, CD112, and CD155. Cytotoxic effects of NK
cells are determined by the balance between NK cell-
activating and inhibiting signals; when the activating sig-
nals are dominant, NK cells have cytotoxic effects [30,
33, 38]. Since human leukemia K562 cells do not express
MHC class I molecules, NK cells showed superior killing
effects to K562 cells compared with U-87 MG cells in
this study.
Moreover, distribution of NK cells in vivo could be an
important determinant of their therapeutic effects. In
this study, we observed that the treatment efficacy of
intratumoral injection of NK cells is better than intra-
venous injection; 1 × 104 NK cells transplanted intratu-
morally showed similar therapeutic effects to 1 × 107
intravenously transplanted NK cells. When we compared
NK cell distribution in the orthotopic GBM xenograft
tumors, similar densities of NK cells were observed in
the 1 × 104 intratumor and 1 × 107 intravenous groups.
Ratios of TUNEL-positive apoptotic cells to CD56 posi-
tive NK cells in the tumor (2 ~ 3:1) was also similar in
those groups. Since NK cells do not distribute in the
brain, techniques that increase the NK cell number in
the GBM would increase the therapeutic effects of NK
cells against the intracranial tumor. Accordingly, when
NK cells were intravenously transplanted more inten-
sively to increase the NK cell/tumor cell ratio, the treat-
ment effects of NK cells were significantly potentiated in
this study.
Immunotherapies such as dendritic cells, lymphocytes,
engineered T-cells, and cancer vaccines, have shown
treatment effects on patients with various metastatic
solid tumors [39–42]. Cellular immunotherapeutic strat-
egies directly target metastatic cancer cells combined
with cytotoxic agents or ionizing radiation [43–46].
Fig. 7 Effects of treatment schedule on the treatment effects of intravenous supplementation of Human NK cells. a Experimental schedule illustrated.
b Tumor volumes were determined and compared four weeks after the tumor cell transplantation (n= 7 for each group). Data =mean + SE. ***p < 0.001,
vs. control, **p < 0.01, vs human NK cell treated once a week for three weeks
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Moreover, tumor initiating/cancer stem cells with anti-
genic heterogeneity were suggested to be recognized by
immune cells [47, 48]. Given that extremely rare extra-
cranial metastasis of GBM [49] and sparse distribution
of NK cells in the brain, inhibitory effects of NK cells on
systemic metastasis of GBM cells in vivo in this study
might be mediated by direct interaction between NK
cells and GBM cells in the extracranial sites where NK
cells monitor abnormal cells.
Recent successes of immunotherapy for solid tumors
have generated a resurgence of interest in immunological
therapeutic approaches to GBMs [23, 27, 38, 50–54].
Many immune cell-based therapies have been tried for the
GBM, including dendritic cells, lymphokine-activated
killer cells, NK cells, and cytotoxic T lymphocytes [32, 55].
Among them, NK cells have the strongest cytotoxic activ-
ities against malignant tumor cells and play important
roles in the initiation of subsequent adaptive immunity
[35, 36, 56]. In this study, we generated sufficient human
NK cells in vitro and confirmed their direct-tumor killing
effects against GBM cells both in vitro and in vivo. More-
over, other immune cells, such as mouse macrophages,
could be recruited to the GBM by the NK cell therapy,
which would provoke further immunological reactions to
GBM cells.
Conclusions
In summary, our results suggest that NK cells play an
important inhibitory role in the extra-cranial metastasis
of the GBM and that GBM cells are susceptible to NK
cells. Therefore, supplementation of NK cells is a prom-
ising immunotherapeutic strategy against GBM, which
could be potentiated by techniques that augment direct
cell-to-cell contact between GBM and NK cells.
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